3/12/2024 | BKDDHY | S&P cuts Emergent BioSolutions
|
3/6/2024 | DD | Emergent BioSolutions enters forbearance agreement, amends loans
|
8/31/2023 | BKDDHY | S&P cuts Emergent BioSolutions
|
8/22/2023 | BKDDHY | Moody's prunes Emergent BioSolutions
|
5/18/2023 | BK | Emergent BioSolutions cuts facilities to $300 million, extends to 2025
|
3/3/2023 | BKDDHY | Moody's trims Emergent BioSolutions
|
2/16/2023 | HY | Market Commentary: Emergent BioSolutions, CHS notes rally; Coinbase up; Avaya, Lumen, Rite Aid decline
|
2/16/2023 | DD | Market Commentary: Emergent BioSolutions, CHS rally; Coinbase up; Avaya, Lumen, Rite Aid decline; Adani up
|
2/16/2023 | BKCVDDEMIGPV | Market Commentary: Junk: CHS/Community Health active post-earnings; Service Properties, Emergent Bio jump
|
2/16/2023 | HY | Market Commentary: Junk: CHS/Community Health active post-earnings; Service Properties, Emergent Bio jump
|
1/9/2023 | BKDDHY | Emergent BioSolutions expects restructuring to save over $60 million
|
12/23/2022 | HY | Market Commentary: Market action thin, volatility down; newcomers to distressed debt space draw attention
|
12/23/2022 | DD | Market Commentary: Volatility down, tone upbeat ahead of year-end holidays; distressed debt names increase
|
12/19/2022 | HY | Market Commentary: Revlon trades after plan preview; Sears paper attracts distressed interest; Emergent up
|
12/19/2022 | DD | Market Commentary: Revlon trades after plan preview; Sears paper attracts distressed interest; Emergent up
|
11/14/2022 | BKDDHY | Moody's trims Emergent BioSolutions
|
11/10/2022 | BKHY | S&P slices Emergent BioSolutions
|
10/13/2022 | BKHY | Moody’s cuts Emergent BioSolutions
|
5/2/2022 | BKHY | Moody's cuts Emergent BioSolutions
|
11/10/2021 | BKHY | S&P shifts Emergent view to negative
|
4/30/2021 | BKCVHY | Moody's alters Emergent view to negative
|
4/20/2021 | BKCVDDEMIGPV | Market Commentary: High yield: Morgan Automotive prices; Jazz megadeal on tap; Charter flat; Emergent down again
|
4/20/2021 | HY | Market Commentary: High yield: Morgan Automotive prices; Jazz megadeal on tap; Charter flat; Emergent down again
|
8/5/2020 | BKCVDDEMIGPV | Market Commentary: Howard Hughes, Harvest Midstream, DSLD price; new deals trade up; index turns positive
|
8/5/2020 | HY | Market Commentary: Howard Hughes, Harvest Midstream, DSLD price; new deals trade up; index turns positive
|
8/4/2020 | HY | Market Commentary: Leviathan, Penske, Emergent, Element, Xerox price; Melco adds on; Service, Apache gain
|
8/4/2020 | BKCVDDEMIGPV | Market Commentary: Leviathan, Penske, Emergent, Element, Xerox price; Melco adds on; Service, Apache gain
|
8/4/2020 | HY | New Issue: Emergent BioSolutions sells upsized $450 million 3 7/8% eight-year notes at par
|
8/4/2020 | BKCVHY | Moody’s gives Emergent BioSolutions Ba2, notes Ba3
|
8/4/2020 | BKCVHY | S&P rates Emergent BioSolutions BB, notes BB-
|
8/4/2020 | HY | Emergent BioSolutions expected to price $400 million eight-year notes on Wednesday
|
8/4/2020 | BK | Emergent BioSolutions seeks loan amendment with notes offering
|
10/15/2018 | BK | Emergent lifts revolver to $600 million, adds $450 million term loan
|
10/5/2018 | BK | Emergent BioSolutions draws on credit facility for PaxVax purchase
|
8/28/2018 | BK | Emergent Biosolutions gets $600 million debt commitment
|
11/15/2017 | CV | Market Commentary: Rambus eclipses Quotient in trades; Everbridge to price; Emergent dips; Acorda tanks
|
11/14/2017 | CVLM | Emergent BioSolutions to terminate conversion rights of 2.875% notes
|
10/2/2017 | BK | Emergent BioSolutions enters into $200 million five-year revolver
|
8/12/2016 | CV | Emergent BioSolutions lowers conversion price of 2.875% convertibles
|
2/4/2014 | BK | Emergent repays $62 million of revolver, terminates unused term loan
|
1/27/2014 | CV | Emergent greenshoe ups 2.875% seven-year convertibles to $250 million
|
1/24/2014 | CV | Market Commentary: Midday Commentary: Emergent BioSolutions up on hedge; Colony Financial 'still wrapped around 100'
|
1/24/2014 | CV | Market Commentary: New Emergent BioSolutions rises on hedge; International Game drops; Exterran sees sellers
|
1/23/2014 | CV | New Issue: Emergent prices $215 million seven-year convertibles at 2.875%, up 37.5%
|
1/23/2014 | CV | Market Commentary: New Colony mostly flat, old Colony 'comes in'; Emergent looks 'fine'; China names in focus
|
1/22/2014 | CV | Emergent BioSolutions offers $200 million seven-year convertibles at 2.625%-3.125%, up 27.5%-32.5%
|
1/22/2014 | CV | Market Commentary: Nuance flat to lower on swap after improved guidance; Colony Financial, Emergent on tap
|
12/12/2013 | BK | Emergent enters $100 million revolver, $125 million term loan
|
5/3/2012 | CVIGPF | Emergent BioSolutions files $180 million stock, debt, preferreds shelf
|
11/12/2008 | CVIG | Emergent BioSolutions files $100 million shelf
|
11/15/2006 | BT | Market Commentary: Emergent BioSolutions sinks on debut; Alexion stock deal on deck; Trimeris zooms on restructuring
|
11/15/2006 | BT | New Issue: Emergent BioSolutions raises $62.5 million in IPO of 5 million shares at $12.50 each
|
10/24/2006 | BT | Emergent BioSolutions talks upcoming IPO at $14-$16 per share
|
8/14/2006 | BT | Emergent BioSolutions files for $86.25 million IPO
|
12/5/2005 | BT | Covalent, Emergent BioSolutions sign Anthrax immune globulin development contract
|